225Ac-HuM195
225Ac-HuM195 Uses, Dosage, Side Effects, Food Interaction and all others data.
Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).
| Trade Name | 225Ac-HuM195 |
| Generic | Lintuzumab satetraxetan AC-225 |
| Lintuzumab satetraxetan AC-225 Other Names | 225Ac-HuM195, 225Ac-lintuzumab, Actinium (225ac) lintuzumab satetraxetan, Actinium AC 225 lintuzumab, Actinium AC-225 lintuzumab, Actinium-225-labeled humanized anti-cd33 monoclonal antibody HUM195, HUM-195 AC-225, Lintuzumab actinium Ac-225, Lintuzumab satetraxetan AC-225 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here 225Ac-HuM195
